Hepatitis C Marketing: Applying Primary Care Tactics To Specialty Products
The Food and Drug Administration's back-to-back approvals of Hepatitis C therapies from Merck & Co. and Vertex Pharmaceuticals set the stage for a specialty-focused marketing battle the likes of which the biopharma industry hasn't seen in years.
You may also be interested in...
With its hepatitis C protease inhibitor progressing in Phase III, Medivir starts to transform itself into a profitable specialty pharmaceutical company.
Roche will co-promote Merck's Victrelis with its own HCV drugs Pegasys and Copegus in the U.S.
Hepatitis C drug development is almost exclusively focused on small molecule oral therapies. Of the 54 compounds in clinical development, just two aim to improve upon injectable interferon, the molecule that forms the backbone of current standard of care. It would be tempting to write them off, but a funny thing happened on the way to the interferon-free future.